Trial Profile

A Phase 1, Randomized, Placebo-Controlled, Double Blind Single Ascending Dose Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPL84

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SPL 84 (Primary)
Indications Cystic fibrosis
Focus Adverse reactions; First in man; Proof of concept
Sponsors SpliSense

Most Recent Events

11 Jan 2024 Status changed from recruiting to completed.
06 Sep 2023 According to a SpliSense media release, encouraging Phase 1 clinical trial results published in Nucleic Acid Therapeutics.
06 Sep 2023 Results from phase 1 portion (n=32; healthy male volunteers) published in a SpliSense media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com